Bavarian Nordic — November 2019
-
danske hæver target på zeal
til 315 -
-
Her er hvad Jefferies skriver om Zeal: Jefferies analyst Peter Welford downgraded Zealand Pharma to Hold from Buy with a price target of DKK235.00, up from DKK185.00. His recent survey of U.S. physicians and recent script trends drive confidence that the launch of ready-to-use glucagon rescue devices will expand the market, but commercial execution is now a risk given the plan to self-commercialize lead asset dasiglucagon HypoPal device as likely third to market, Welford tells investors.
-
(fortsat) He thinks Zealand shares appear fully valued and he sees a lack of a major near-term catalysts, the analyst added.
-
Ang. analytikeranbefalinger vil jeg sige, at jeg ikke rigtig synes de har holdt omkring Zealand. Aktuelt Jefferies: Man kunne vel også mene, at med deres nye kursmål må de da mene, at den skal holdes. Og så kan de senere sætte den op igen, når den øvrige pipeline bryder frem. I det hele taget er disse kortsigtede betragtninger ikke meget værd i et transformationsselskab.
-
En ganske logisk dag!
Ikke helt utænkeligt at ZP måske vil falde længere ned.
Med lidt held kan der måske suppleres i intervallet kurs 180 - 210 ...
Iflg. Investtech: "Ved reaktioner tilbage har aktien støtte ved cirka 156 kroner."
Men det er vist ønsketænkning at ZP kommer til at falde så meget.
-
Der bliver godt nok uddelt tæsk til biotek idag. Der har selvfølgelig også været fine stigninger, men det ser lidt voldsomt ud.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind